Exploring alternatives to tumor tissue for BRCA1/2 next‐generation sequencing testing in high‐grade serous ovarian cancer: A 34‐case series of malignant ascites
Cancer Cytopathology · 2026-05 · 134 (5)
DOI: 10.1002/cncy.70102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cytopathology, online erschienen am 27.04.2026. Verfasst von Chiara Pighi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy. Hauptthemen laut MEDLINE: Ovarian Neoplasms, High-Throughput Nucleotide Sequencing, Ascites, BRCA2 Protein. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
BRCA1/2 testing is currently recommended at diagnosis for high‐grade serous ovarian carcinoma (HGSOC) because of its impact on patients' survival when treated with poly(adenosine diphosphate ribose) polymerase inhibitors. Standard clinical practice involves analyzing BRCA1 / 2 genes in formalin‐fixed, paraffin‐embedded (FFPE) histological specimens. However, because neoplastic ascites is a common clinical presentation in HGSOC and provides a good source of neoplastic cells via a less invasive procedure, it is worthwhile to explore the feasibility of BRCA1/2 testing on cytological specimens obtained from malignant ascites.
Methods
BRCA1/2 status was analyzed in 34 ascites‐derived cytological samples via an amplicon‐based next‐generation sequencing (NGS) approach, and the results were compared with those from FFPE tissues previously tested in routine clinical practice.
Results
A perfect match was observed between BRCA1 / 2 testing results from neoplastic ascites and surgical samples (100% concordance) for all pathogenic variants, including both germline and somatic mutations. This is the first study to report such high concordance within the largest collection of somatic variants analyzed to date. Additionally, molecular NGS testing was demonstrated to be feasible even in malignant ascites with a low tumor fraction and with archived material.
Conclusions
This study shows that ascites can be a suitable specimen for BRCA1/2 NGS testing, and provides a minimally invasive option for disease diagnosis and the early detection of key molecular biomarkers essential for the clinical management of women with HGSOC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
- Medical Genetics, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
- Gynecologic Oncology and Minimally Invasive Pelvic Surgery, Department of Obstetrics and Gynecology, International School of Surgical Anatomy, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Ita…
- Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
- Pathology Unit, Department of Woman and Child's Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
- Pathology Institute, Catholic University of Sacred Heart, Rome, Italy.
ORCID-Profile: Gian Franco Zannoni, Anna Pesci
Zitieren
APA
Pighi, C., Settanni, G., Angelini, M., Bortesi, L., Viassolo, V., Ceccaroni, M., Bruni, F., Gori, S., Zannoni, G. F., & Pesci, A. (2026). Exploring alternatives to tumor tissue for BRCA1/2 next‐generation sequencing testing in high‐grade serous ovarian cancer: A 34‐case series of malignant ascites. Cancer Cytopathology, 134(5). https://doi.org/10.1002/cncy.70102
Vancouver
Pighi C, Settanni G, Angelini M, Bortesi L, Viassolo V, Ceccaroni M, et al. Exploring alternatives to tumor tissue for BRCA1/2 next‐generation sequencing testing in high‐grade serous ovarian cancer: A 34‐case series of malignant ascites. Cancer Cytopathology. 2026;134(5). doi:10.1002/cncy.70102
BibTeX
@article{Pighi2026,
author = {Pighi, Chiara and Settanni, Giulio and Angelini, Marta and Bortesi, Laura and Viassolo, Valeria and Ceccaroni, Marcello and Bruni, Francesco and Gori, Stefania and Zannoni, Gian Franco and Pesci, Anna},
title = {Exploring alternatives to tumor tissue for BRCA1/2 next‐generation sequencing testing in high‐grade serous ovarian cancer: A 34‐case series of malignant ascites},
journal = {Cancer Cytopathology},
year = {2026},
volume = {134},
number = {5},
doi = {10.1002/cncy.70102}
}
EUVIMED